![]() The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines. On the date of publication, Joel Baglole did not have (either directly or indirectly) any positions in the securities mentioned in this article. This is a positive end to a drawn out process that required Novavax to overcome multiple hurdles on the way to getting its vaccine across the finish line. While official approval has yet to come from the FDA, NVAX stock is climbing on expectations the company’s Covid-19 vaccine will be cleared for widespread use in short order. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes. President Joe Biden’s administration is working on a plan that will make all adults eligible for a booster in an attempt to mitigate the effects of contagious omicron subvariants. The vaccine contains Novavax’s (Nasdaq: NVAX) Matrix-M, a saponin-based adjuvant that enhances the immune system response, making it more potent and more durable. The FDA has approved Covid-19 vaccines for people aged six months and older. government prepares for an uptick in cases this summer as well as an expected resurgence of Covid-19 during cold and flu season this winter. The White House’s purchase of more than three million doses of Novavax’s vaccine also boosts the company’s fortunes. Novavax has said in the past it plans to concentrate sales of its vaccine on developing nations that have struggled to secure supplies of Covid-19 shots. might not be the primary market for Novavax’s Covid-19 shot given most of the population is already fully inoculated. This is the first vaccine that Novavax has successfully commercialized. Many analysts and investors had doubted whether the company’s Covid-19 vaccine would ever be approved in the U.S. The FDA approval is a huge victory and vote of confidence in Novavax. However, Novavax’s protein-based vaccine could be used in people who are allergic to components of the messenger RNA vaccines offered by Pfizer and Moderna, or who are concerned about those vaccines’ newer technology. Meanwhile, competing inoculations from Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) beat Novavax to market. But Novavax has endured two years of delays and setbacks in getting FDA approval for its vaccine. Novavax’s vaccine was viewed to be one of most promising inoculations against Covid-19 - so much so that former President Donald Trump’s administration pre-ordered 110 million doses at a cost of $1.6 billion. Centers for Disease Control and Prevention (CDC). Two-thirds (67%) of the American population are already fully vaccinated against the respiratory illness, according to the U.S. Politico is reporting the FDA is set to greenlight Novavax’s two-dose Covid-19 vaccine for use in adults. While this news and the order from the federal government are positive developments, Novavax’s Covid-19 vaccine comes to market late.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |